Our mammalian-based bispecific expression combines best-in-class CLD with unmatched expertise and experience in mammalian-based contract development and manufacturing. We prioritize quality, efficiencies, and time savings in bsAb production across a diverse portfolio of molecule formats. Learn more: https://hubs.la/Q02Z6BSG0
关于我们
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI is proud to be a JSR Life Sciences Company.
- 网站
-
https://www.kbibiopharma.com
KBI Biopharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Durham，North Carolina
- 类型
- 私人持股
- 创立
- 1996
- 领域
- CLD、Process Development、Manufacturing、Mass Spectrometry、Fermentation、Cell Culture、Analytical、Purification、Release & Stability、Formulation、Modeling & Simulation、Particle Characterization、Biophysical Characterization、CHO HCP、ultracentrifugation、AUC和cell therapy logisitcs
地点
KBI Biopharma员工
-
Tracey Braun
-
John Ferrero
IT Director and Business Partner delivering technology solutions to international pharmaceutical and life science organisations.
-
Dr. Dorothea Jeffery Anderson
Cross-Functional Leader | Patient-Centered Pharmaceutical Development | Program Management | Tech Transfer | DEI Change Agent | Non-Profit Board…
-
Cheryl Ames
Sr Product Owner KBI Biopharma
动态
-
Check out this deep dive into the critical role of AAV characterization in advancing gene therapy. Our comprehensive approach ensures consistency, safety, and efficacy for AAV-based therapies:
How does KBI Biopharma enhance safety in AAV gene therapy? ?? KBI Biopharma’s comprehensive AAV characterization approach, including techniques like SEC-MALS and nano-DSF, allows precise quality control of AAV capsids. These methods ensure batch-to-batch consistency and target immune responses effectively, making AAV-based therapies safer for patients. ?? As the demand for gene therapy rises, KBI’s expertise is critical in advancing successful AAV therapeutics, offering new hope for complex genetic conditions. ?? Full article below! ?? https://lnkd.in/dcC45Rmf #genetherapy #AAVcharacterization #precisionmedicine #biotechinnovation #neuromusculardiseases #therapeuticadvances #advancedtechniques
-
Streamline your analytics ordering and sample coordination with the KBI Biopharma Analytical Portal. Say goodbye to the back-and-forth emails and enjoy seamless access to quotes, sample submissions, and project tracking—all in one convenient platform. Our user-friendly portal connects you directly with subject matter experts, providing the information you need quickly to keep your projects moving efficiently. Learn how our Analytics Portal can enhance your workflow: https://hubs.ly/Q02Xx8K-0 #KBIBiopharma #CDMO #AnalyticalServices
-
-
Please join us today in expressing sincere gratitude to the many brave service members that have served in the US Military, including those that now work at KBI Biopharma and within the JSR Life Sciences network. Your unwavering commitment to the greater good, both in uniform and in your roles today, is truly inspiring. We thank you for your dedication to serving your communities and our country, and are immensely grateful for your courage, strength, and resilience. #VeteransDay2024 #Gratitude #KBIBiopharma
-
-
CDMO selection is a complex process. Sigma Mostafa discusses how to select the right partner with David Bruehlmann in his latest podcast episode. You'll gain valuable insights from her many years of experience. Listen now! #kbibiopharma #cdmo #partnership #biotech
Fractional CTO - Helping biotech leaders turn biologics and technologies into commercial products | CMC Development and Manufacturing | Project Management | Business Strategy
What CDMO should I choose? If this question keeps you up at night, you're not alone. With millions in development costs at stake, the wrong choice could derail your entire biologics program. I recently sat down with Sigma Mostafa, Chief Scientific Officer at KBI Biopharma, to decode the complexities of CDMO selection and partnership. What we discussed will transform your decision-making process: ? Why specialized CDMOs often outperform one-stop shops ? How AI and machine learning are revolutionizing protein sequence analysis ? Critical factors in cell line selection that impact long-term success ? Innovative strategies to accelerate development without compromising quality If you're tired of the guesswork in CDMO selection and ready to make data-driven decisions, this episode is your roadmap to success. Ready to choose your CDMO partner with confidence? Listen now to gain insights that will impact your project's trajectory for years to come. #Biotech #BiologicsDevelopment #CDMO #BioprocessDevelopment #BiotechInnovation
-
There's still time to connect with our team at #BIOEurope in Stockholm!
Director Business Development and Licensing EMEA, KBI Biopharma | PhD in Molecular Neuroimmunology
Hello #BIOEUROPE, Hello Stockholm! KBI Biopharma is here, and we love the kanelbulle. Thank you. Please do stop by to say hello to Elodie POTHIN, Dr. Sabrina Schubert, Fabian Friedl and me!
-
-
Today’s Team Member Tuesday is Logan Behlke, Associate Director of Downstream Manufacturing at our Hamlin Road facility in Durham, North Carolina. Logan oversees all aspects of our downstream processing readiness and execution at the site – which is a 24/7/365 operation consisting of four manufacturing shifts and a specialist team. He says, “I’ve been fortunate to work alongside some of the most talented, driven and passionate people I’ve ever met here at KBI. Through the years it has been rewarding to work and creatively problem-solve with like-minded individuals, all towards a common goal. It should always begin and end with people, when teams buy-in and are working together, looking out for each other, success will follow. The work we do has tremendous impact for patients in need and I’m honored to be a part of it.” Outside of work, Logan enjoys playing golf, cheering on the Heels, and spending time with friends and family. He also enjoys traveling with his wife, Christy, and they recently spent time in Italy and Norway. #KBIBiopharma #TeamMemberTuesday
-
-
Can precise AAV characterization improve gene therapy outcomes? ?? KBI Biopharma is pioneering advanced techniques like Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) to ensure AAV therapies are safe and effective. By analyzing AAV capsid filling states – whether capsids are empty, underfilled, or overfilled – KBI helps improve gene therapy’s accuracy and reduce risks. ?? This approach to quality control is essential for developing reliable gene therapies for conditions like neuromuscular and cardiovascular diseases. ???? Read more below! ?? https://lnkd.in/dcC45Rmf #genetherapy #AAVcharacterization #precisionmedicine #biotechinnovation #neuromusculardiseases #therapeuticadvances #advancedtechniques??
Unlocking AAV gene therapy potential: The role of successful characterization
https://www.labiotech.eu
-
We're excited to share that the KBI Biopharma Analytics Portal has a new look! See what’s new: https://hubs.la/Q02WNR9C0 Our Analytics Portal is a one-stop-shop for quote requests, ordering, sample submission, project progress tracking, and more. Say goodbye to back-and-forth emails – connect directly with subject matter experts, providing the information you need quickly to keep your projects moving efficiently. #KBIBiopharma
-
-
Come see us at BIO-Europe, November 4–6, 2024, in Stockholm, Sweden, to learn more about how our services and solutions can take your company to the next level. Register a last minute meeting with us or stop by booth #62. KBI Biopharma
-